Intermittent metronomic drug schedule is essential for activating antitumor innate immunity and tumor xenograft regression.

ABSTRACT: Metronomic chemotherapy using cyclophosphamide (CPA) is widely associated with antiangiogenesis; however, recent studies implicate other immune-based mechanisms, including antitumor innate immunity, which can induce major tumor regression in implanted brain tumor models. This study demonstrates the critical importance of drug schedule: CPA induced a potent antitumor innate immune response and tumor regression when administered intermittently on a 6-day repeating metronomic schedule but not with the same total exposure to activated CPA administered on an every 3-day schedule or using a daily oral regimen that serves as the basis for many clinical trials of metronomic chemotherapy. Notably, the more frequent metronomic CPA schedules abrogated the antitumor innate immune and therapeutic respo

SUBMITTER: Chen CS 

PROVIDER: S-EPMC3924543 | biostudies-literature | 2014 Jan

REPOSITORIES: biostudies-literature